Open Access<p>Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells</p>
Author(s) -
Xuewen Wang,
Bing Chen,
Danfen Xu,
Zhijun Li,
Yuxia Sui,
Xinhua Lin
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s255586
Subject(s) - lung cancer , cisplatin , apoptosis , chop , cancer research , medicine , cancer , cancer cell , cell growth , a549 cell , chemotherapy , biology , pathology , biochemistry
The incidence and mortality of lung cancer continue to increase around the world; in 2018, new lung cancer cases accounted for 11.6% of all cancer cases, and lung cancer deaths accounted for 18.4% of cancer deaths. Cisplatin (DDP) is a first-line chemotherapy drug for lung cancer; however, DDP resistance can lead to a poor prognosis in patients with lung cancer. Therefore, reversing DDP resistance is a treatment goal.